Participation in Genetic Studies IS of great Need
Click HERE to Subscribe for the MS Beacon Newsletter Overview NOTE: The COVID-19 pandemic may affect the…
AbbVie gets orphan drug and fast track status for Elezanumab – for Myelin repair
29 September 2020 (Last Updated September 29th, 2020 12:36) AbbVie has received orphan drug and fast track designations from the…
Stuart Schlossman
Satralizumab Shows Safe Profile in Patients With NMOSD (NMO)
Benjamin Greeberg, MD Results from the combined double-blind and open-label extension periods of the SAkuraSky (NCT02028884) and SAkuraStar (NCT02073279) clinical…
Stuart Schlossman
Money Management in Multiple Sclerosis: The Role of Cognitive, Motor, and Affective Factors
Yael G1,2, Nancy C2,3, John D2,3. Author information 1 Department of Occupational Therapy, New York University, New York, NY, United States. 2…
Stuart Schlossman
Does Anesthesia, Invasive Surgery Increase Multiple Sclerosis Relapse Risk?
Hesitation to put MS patients on the operating table, due to relapse risk, may have physicians delaying important surgeries unnecessarily.…
Stuart Schlossman
The Dangers of Influenza and Benefits of Vaccination in Adults with Chronic Health Conditions
Experts stress the importance of protecting adults with chronic health conditions from influenza The recommendations in this Call to Action…
Stuart Schlossman
Prevalence of MS More Than Doubles Estimate
A new study funded by the National MS Society has confirmed that nearly one million people are living with MS…
Stuart Schlossman
What are Clinical Trial Phases?
In the United States, medications and medical devices can’t reach patients without being approved by the Food and Drug Administration…
Stuart Schlossman
Minority Engagement in MS Research
FEBRUARY 1, 2018 BY LAURA KOLACZKOWSKI Engaging all types of people for research isn’t just a nice thought. It…
Stuart Schlossman
Lifetime Cancer Risk Lower in MS Patients Than General Public, Study Reports
December 26, 2017 People with multiple sclerosis (MS) have a lower overall lifetime risk of cancer relative to a general…
Stuart Schlossman
